Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Suspended 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Breast 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Resectable Esophageal Cancer 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Oxaliplatin 300Fluorouracil 272Bevacizumab 237Gemcitabine 236Leucovorin 212Capecitabine 207pembrolizumab 201Nivolumab 158Irinotecan 158Cisplatin 150Specimen Handling 144Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 118Paclitaxel 109durvalumab 107Cetuximab 104Radiotherapy 99atezolizumab 94Drug Therapy 94Biopsy 93tislelizumab 81Albumin-Bound Paclitaxel 81Taxes 74Folfox protocol 68lenvatinib 67Carboplatin 66regorafenib 60Blood Specimen Collection 60sintilimab 54Ipilimumab 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adjuvants, Immunologic × Gastrointestinal × 1 year × Clear all
NCT06130826 2026-06-03

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

City of Hope Medical Center

Phase 1 Suspended
24 enrolled
BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT05307835 2025-12-02

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Active not recruiting
27 enrolled
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡